Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | APLNR | P35414 | 2/20 | 0.38 |
| ▸ | CTSH | P09668 | 1/20 | 0.38 |
| ▸ | TFPI | P10646 | 1/20 | 0.37 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.37 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.37 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725918 | 0.88 | SLC15A2 (0.35) | NMT2NMT1APLNRC5AR1SLC15A2 | |
| SCHEMBL3731630 | 0.86 | NMT1 (0.48) | NMT2NMT1TFPIOPRL1QRFPR | |
| SCHEMBL3731142 | 0.86 | NMT1 (0.42) | NMT2NMT1APLNRC5AR1 | |
| SCHEMBL29614488 | 0.84 | CTSL (0.46) | CTSLCTSSCTSKAPLNRCTSH | |
| SCHEMBL29614491 | 0.84 | CTSL (0.46) | CTSLCTSSCTSKAPLNRCTSH | |
| SCHEMBL14479383 | 0.81 | TFPI (0.46) | CTSLCTSSCTSKAPLNRCTSH | |
| SCHEMBL29614462 | 0.79 | TFPI (0.46) | CTSLCTSSCTSKAPLNRCTSH | |
| SCHEMBL31437155 | 0.79 | SLC15A2 (0.44) | CTSLCTSSCTSKAPLNRCTSH | |
| SCHEMBL30595069 | 0.79 | SIRT6 (0.41) | IL23RSLC15A2 | |
| SCHEMBL26446682 | 0.79 | SLC15A2 (0.48) | F2C5AR1SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | F2 3508/4885NMT2 755/4885NMT1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.